SPY366.04+3.98 1.10%
DIA299.99+3.37 1.14%
IXIC12,319.04+120.30 0.99%

Burning Rock Announced In-Licensing of Myriad myChoice Tumor Testing in China

Burning Rock Biotech Limited (NASDAQ: BNR) announced that it entered into a development and commercialization agreement with Myriad Genetics, Inc. (NASDAQ:MYGN, "Myriad"))) which will bring myChoice® tumor testing for homologous recombination deficiency, or HRD, to China.

· 11/16/2020 05:49
Burning Rock Biotech Limited (NASDAQ:BNR) announced that it entered into a development and commercialization agreement with Myriad Genetics, Inc. (NASDAQ:MYGN, "Myriad")))) which will bring myChoice® tumor testing for homologous recombination deficiency, or HRD, to China. The Myriad myChoice CDx test enables physicians to identify patients with tumors that have lost the ability to repair double-stranded DNA breaks, resulting in potentially increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. In May 2020, the U.S. Food and Drug Administration (FDA) approved myChoice CDx for use as a companion diagnostic to identify patients with advanced ovarian cancer with HRD-positive status, who are eligible or may become eligible, for first-line maintenance treatment with Lynparza (olaparib) in combination with bevacizumab. In August 2020, myChoice was exclusively cited and the only named commercial companion diagnostic by the American Society of Clinical Oncology in new recommendations on the use of PARP inhibitors for the treatment and management of certain patients with advanced ovarian cancer. The new recommendations, based on clinical trial results, were published in the Journal of Clinical Oncology. Through the partnership with Myriad, Burning Rock will perform myChoice HRD testing in China for collaborative drug development studies and for clinics. "The myChoice test is highly synergistic with Burning Rock's existing testing platforms. With the growing significance demonstrated on PARP inhibitors in a range of cancer types, HRD has become an important yet challenging characteristic to identify for patients with cancer, while myChoice has been regarded as the ‘gold-standard' for determining HRD status. We are excited to bring in this best-in-class HRD test for the benefit of Chinese patients, leveraging Burning Rock's strengths in oncology NGS testing and commercial access in China," said Yusheng Han, CEO of Burning Rock. "Through close collaboration with Burning Rock in China, we are bringing the clinical benefits of myChoice testing to additional markets and patients, advancing personalized treatment for patients around the world," said Nicole Lambert, president of Myriad Genetic Laboratories.